X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.business-standard.com/companies/news/biocon-leads-india-s-push-into-anti-obesity-drugs-as-patents-lapse-124040800028_1.html
https://www.indianpharmapost.com/drug-approval/biocon-to-obtain-approval-for-diabetes-drug-liraglutide-in-uk-15447
https://www.fiercepharma.com/pharma/glp-1-drugs-novo-az-lilly-and-sanofi-under-uk-probe-over-their-suicide-risks-reuters
https://www.fiercepharma.com/pharma/obesity-drug-shortage-expands-saxenda-novo-nordisk-warns-limited-supply-2023-and-beyond
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-extends-ozempic-probe-include-other-drugs-2023-07-11/
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-probes-novos-weight-loss-drugs-reports-suicide-risks-bloomberg-news-2023-07-10/#:~:text=July%2010%20(Reuters)%20%2D%20The,about%20suicide%20or%20self%2Dharm
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208583
https://www.prnewswire.com/news-releases/sciwind-biosciences-to-highlight-positive-clinical-data-for-glp-1-peptide-agonist-ecnoglutide-xw003-at-the-american-diabetes-association-ada-83rd-annual-conference-301858192.html
https://www.fiercepharma.com/manufacturing/novo-nordisks-earlier-weight-loss-med-saxenda-pulls-down-record-sales-wegovy-supply
https://www.reuters.com/article/us-novo-nordisk-wegovy/risk-of-patient-overlap-between-wegovy-and-saxenda-obesity-drugs-novo-says-idUSKCN2DJ0NR
https://www.reuters.com/world/americas/brazil-cases-dropping-relaxing-health-measures-could-reverse-gains-paho-2021-04-21/
http://www.pharmatimes.com/news/novo_nordisks_saxenda_bags_nice_recommendation_1355828
https://www.fiercebiotech.com/biotech/novo-nordisk-scraps-type-1-diabetes-drug-after-phase-2-trial
https://www.pharmaceutical-technology.com/news/nice-novo-nordisk-obesity/
http://www.pharmafile.com/news/562817/nice-recommends-novos-liraglutide-management-obesity-and-non-diabetic-hyperglycaemia
https://www.fiercepharma.com/pharma/mylan-challenge-to-novo-s-victoza-results-ptab-review
http://www.pmlive.com/pharma_news/novo_nordisks_first_semaglutide_obesity_trial_hits_the_mark_1340272
https://markets.businessinsider.com/news/stocks/saxenda-demonstrated-improvements-in-bmi-and-body-weight-in-adolescents-with-obesity-1029050036
https://www.fiercebiotech.com/research/insights-into-how-novo-nordisk-s-saxenda-reduces-food-cravings-may-inspire-new-obesity
http://www.pharmatimes.com/news/nihr_to_invest_59m_in_amr,_air_pollution_and_infectious_diseases_1323475
https://www.fiercepharma.com/pharma/looking-for-big-obesity-push-novo-nordisk-gets-uk-pushback-instead-for-saxeda
https://www.fiercebiotech.com/biotech/novo-drops-oral-glp-1-analog-to-focus-next-gen-rybelsus
http://www.pharmatimes.com/news/oral_semaglutide_trumps_jardiance,_januvia,_victoza_in_type_ii_diabetes_1302027
https://www.fiercepharma.com/pharma/easd-novo-s-ozempic-tops-invokana-victoza-double-head-to-head-win
https://www.clinicaltrialsarena.com/news/novo-nordisk-oral-semaglutide/
https://www.fiercepharma.com/pharma/easd-novo-s-ozempic-tops-invokana-victoza-double-head-to-head-win
https://www.fiercepharma.com/marketing/novo-nordisk-rolls-out-authorized-insulin-generics-following-similar-moves-by-lilly-and
https://www.biospace.com/article/novo-nordisk-sues-mylan-to-prevent-generic-version-of-diabetes-drug-victoza/
https://www.biopharmadive.com/news/novo-faces-shareholder-suit-over-insulin-sales-disclosures/561091/
https://www.fiercepharma.com/pharma/novo-s-ozempic-launch-kicks-into-gear-ahead-oral-semaglutide-fda-decision
http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946
http://www.pharmatimes.com/news/recent_ozempic,_victoza_data_promising_for_diabetic_kidney_disease_1292426
https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-pediatric-patients-with-type-2-diabetes-300869765.html
https://www.fiercepharma.com/pharma/ada-novo-nordisk-s-oral-semaglutide-posts-another-heart-safety-win
https://www.prnewswire.com/news-releases/oral-semaglutide-showed-superior-reductions-in-blood-sugar-vs-jardiance-and-non-inferior-blood-sugar-reductions-vs-victoza-in-adults-with-type-2-diabetes-at-26-weeks-300864177.html
https://www.cnbc.com/2019/05/03/reuters-america-update-2-novo-nordisk-profit-tops-forecast-as-new-diabetes-drug-shines.html
http://www.pharmatimes.com/news/phase_iii_study_finds_novo_nordisks_victoza_to_be_superior_in_reducing_blood_sugar_in_children_1286000
http://www.pharmatimes.com/news/novo_nordisk_files_for_eu_approval_of_ozempic_in_type_ii_diabetes_1285844
http://www.pmlive.com/pharma_news/novo_nordisk_preps_for_speedy_oral_glp-1_drug_filing_1277020
https://endpts.com/novo-bets-on-swift-fda-review-for-oral-diabetes-drug-semaglutide/
https://www.fiercepharma.com/pharma-asia/lured-by-high-demand-korean-wholesaler-smuggled-novo-s-obesity-med-to-china
https://www.reuters.com/article/us-lilly-trulicity/lilly-says-diabetes-drug-trulicity-reduces-heart-risks-in-trial-idUSKCN1NA1FZ?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/novo-nordisk-expands-job-cuts-to-1-300-as-executives-play-down-lilly-s-glp-1-threat
https://uk.reuters.com/article/us-novo-nordisk-results/novo-nordisk-extends-job-losses-profit-just-misses-forecasts-idUKKCN1N646O
https://www.fiercepharma.com/marketing/novo-nordisk-boosts-its-glp-1-score-yet-more-evidence-for-crucial-semaglutide-pill
https://endpts.com/eli-lilly-picks-up-an-oral-glp-1-from-a-big-roche-sub-for-50m-in-cash-plus-deal-and-its-not-a-peptide/
https://endpts.com/trailing-rivals-astrazeneca-offers-a-hit-and-a-miss-on-key-cardio-study-for-sglt2-diabetes-drug-farxiga/
http://www.pharmatimes.com/news/novo_nordisk_sees_revenues_drop_in_q2_1248067
Market Place
Share 
